Effects of estrogen and related agents upon methamphetamine-induced neurotoxicity within an impaired nigrostriatal dopaminergic system of ovariectomized mice.
Estrogen increases methamphetamine (MA)-induced neurotoxicity within the impaired nigrostriatal dopaminergic (NSDA) system of ovariectomized female mice, as defined by enhanced striatal dopamine (DA) depletion. In this study we compared the effects of a lower dose of estradiol benzoate (EB, 1 microg) with related agents--tamoxifen (TMX, 12.5 microg), testosterone (5 microg) and dehydroepiandrosterone (DHEA, 3 mg) in this paradigm. In experiment 1, ovariectomized mice received an initial treatment with MA. At 1 week after MA, mice were treated with EB, TMX, testosterone, DHEA or oil vehicle and 24 h later a second MA treatment. Striatal DA and 3,4-dihydroxyphenylacetic acid (DOPAC) concentrations in the MA-treated groups were decreased compared to the non-MA-treated control. Neither EB nor any of the other agents tested showed enhanced neurodegenerative or neuroprotective effects against a second MA invasion. To verify that estrogen was capable of showing a neuroprotective effect under a condition of two administrations of MA, in experiment 2, EB was administered either once or twice prior to each of the two MA treatments. EB treatment prior to the first MA invasion or first and second MA protected the NSDA system against DA and DOPAC depletion. These results imply that a lower dose of EB, TMX, testosterone and DHEA cannot exert neurodegenerative or neuroprotective effects in the impaired NSDA model. However, EB administered prior to the introduction of neurotoxicity can protect the NSDA system. This study may provide an understanding of the variations in results on the effects of estrogen upon the NSDA neurodegenerative disorder, Parkinson's disease.
Liu
Bin
B
Department of Anatomy, Northeastern Ohio Universities College of Medicine, Rootstown, Ohio 44272-0095, USA.
Dluzen
Dean E
DE
D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism; D000728:Androgens / Q000008:administration & dosage; D000818:Animals; D004298:Dopamine / Q000378:metabolism; D015259:Dopamine Agents / Q000008:administration & dosage* / Q000633:toxicity; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004958:Estradiol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000502:physiology; D004965:Estrogen Antagonists / Q000008:administration & dosage; D005260:Female; D008694:Methamphetamine / Q000008:administration & dosage* / Q000633:toxicity; D051379:Mice; D017072:Neostriatum / Q000187:drug effects* / Q000378:metabolism; D009410:Nerve Degeneration / Q000139:chemically induced / Q000517:prevention & control; D018696:Neuroprotective Agents / Q000008:administration & dosage; D009498:Neurotoxins / Q000008:administration & dosage*; D010052:Ovariectomy; D010300:Parkinson Disease / Q000503:physiopathology; D013378:Substantia Nigra / Q000187:drug effects* / Q000378:metabolism; D013629:Tamoxifen / Q000008:administration & dosage
D000728:Androgens; D015259:Dopamine Agents; D004965:Estrogen Antagonists; D018696:Neuroprotective Agents; D009498:Neurotoxins; D013629:Tamoxifen; D015102:3,4-Dihydroxyphenylacetic Acid; C074283:estradiol 3-benzoate; D008694:Methamphetamine; D004958:Estradiol; D004298:Dopamine